ProShares Ultra Nasdaq Biotechnology (BIB)
|Ex-Dividend Date||Sep 21, 2010|
|Day's Range||57.11 - 59.24|
|Inception Date||Apr 8, 2010|
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
Top 10 Holdings65.95% of assets
|NASDAQ Biotechnology Index SWAP Citibank NA||N/A||13.91%|
|NASDAQ Biotechnology Index SWAP Goldman Sachs International||N/A||10.76%|
|NASDAQ Biotechnology Index SWAP Societe Generale||N/A||10.19%|
|NASDAQ Biotechnology Index SWAP Bank of America NA||N/A||8.85%|
|NASDAQ Biotechnology Index SWAP UBS AG||N/A||5.43%|
|Dec 23, 2021||$0.000||Dec 31, 2021|
|Sep 22, 2021||$0.000||Sep 29, 2021|
|Jun 22, 2021||$0.000||Jun 29, 2021|
|Mar 23, 2021||$0.000||Mar 30, 2021|
|Mar 23, 2016||$0.000||Apr 1, 2016|
It's been a hard year for a lot of the biotech industry, with many hedge funds ending the year with significant losses, but there have been a number of shining stars that are expected to continue to off...
The pandemic has triggered a race to introduce vaccines and treatment options, opening up investment opportunities in the biotech sector.
This has been a pivotal week for biotech news, as Johnson & Johnson said Wednesday that a booster shot of its COVID-19 vaccine generated a promising immune response in early stage clinical trials. This ...
Investors could easily tap the bullish trend by considering a near-term long on the biotech sector.
The FDA has officially given full approval to Pfizer and BioNTech for their COVID-19 vaccine, potentially making way for more approvals and more vaccine mandates, reports CNBC. It is a move that officia...
There could be big gains ahead for biotech ETFs, as the Food and Drug Administration on Monday fully approved the Pfizer and BioNTech coronavirus vaccine, making it the first vaccine in the U.S. to be a...
As the Delta variant sweeps across the globe, pharmaceutical and biotech companies are working to ensure vaccines continue to cover the population, as well as working on booster doses that can adapt to ...
From vaccine-related progress to development of cell therapies for the treatment of coronavirus, all kept the rally in the biotech sector alive.